Month: September 2020

Paris, le 11 septembre 2020En amont de la publication des Résultats annuels de l’exercice 2019-2020 le 29 octobre prochain, Sodexo annonce que la performance du quatrième trimestre de l’exercice 2019-2020 est en ligne avec les hypothèses pour le second semestre publiées le 7 juillet 2020 en ce qui concerne le chiffre d’affaires, l’impact sur le résultat d’exploitation et les liquidités générées par les opérations grâce à la forte mobilisation de ses équipes pleinement engagées.Le Groupe est extrêmement confiant quant à sa capacité à tirer le meilleur profit des tendances qui se profilent, grâce à son positionnement unique, son portefeuille diversifié de services et sa solidité financière.Dans le prolongement des mesures rigoureuses mises en œuvre durant la crise sanitaire, le Groupe, en anticipation de la fin des programmes...

Pratteln, Switzerland, September 11, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces that partner ReveraGen Biopharma Inc. has completed enrollment into the pivotal VISION-DMD study with vamorolone in patients with Duchenne muscular dystrophy (DMD). Subject to a positive study outcome, this could allow for a regulatory submission to the US FDA in the fourth quarter of 2021 with the potential to offer an alternative to current standard of care in young boys with DMD.The 48-week Phase 2b VISION-DMD study (VBP15-004; clinicaltrials.gov: NCT03439670 [1]) is designed as a pivotal trial to demonstrate efficacy and safety of vamorolone administered orally at doses of 2.0 mg/kg/day and 6.0 mg/kg/day versus prednisone 0.75 mg/kg/day and placebo in ambulant boys ages 4 to

Pratteln, Schweiz, 11. September 2020 – Santhera Pharmaceuticals (SIX: SANN) gibt bekannt, dass das Partnerunternehmen ReveraGen Biopharma Inc. die Rekrutierung für die pivotale VISION-DMD-Studie mit Vamorolone bei Patienten mit Duchenne-Muskeldystrophie (DMD) abgeschlossen hat. Vorbehältlich positiver Studienresultate könnte dies eine Zulassungseinreichung bei der US-FDA im vierten Quartal 2021 ermöglichen mit dem Potential, eine Alternative zur derzeitigen Standardbehandlung bei jungen Knaben mit DMD zu ermöglichen.Die 48-wöchige Phase-2b-Studie VISION-DMD (VBP15-004; clinicaltrials.gov: NCT03439670 [1]) ist als zulassungsrelevante Studie konzipiert, um die Wirksamkeit und Verträglichkeit von Vamorolone in oral verabreichten Dosierungen von 2.0 mg/kg/Tag und 6.0 mg/kg/Tag im Vergleich zu Prednison 0.75 mg/kg/Tag und Placebo bei gehfähigen...

75% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease activity two years after switching to OCREVUS in open-label Phase IIIb CASTING study97% persistence and strong adherence to OCREVUS treatment and twice-yearly dosing schedule from real-world dataOCREVUS is the first and only treatment approved for both relapsing MS (RMS) and primary progressive MS (PPMS) and now more than 170,000 people have been treated with OCREVUS globally in clinical trial and real-world settings; favourable benefit-risk profile remains consistent over 7 yearsBasel, 11 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data that show OCREVUS® (ocrelizumab) is a highly effective treatment option for people with relapsing-remitting multiple sclerosis (RRMS) who...

Coop Pank’s financial results in August 2020:In August, the number of the bank’s customers increased by 1,800 and reached 78,000 by the end of the month. Customer base has grown by 43% over the year.The volume of the bank’s customer deposits increased by 34 million euros, reaching 684 million euros by the end of August. Over the year, the volume of bank deposits has grown by 54%.The bank’s net loan portfolio increased by 11 million euros over the month and reached 583 million euros by the end of August. The loan portfolio has grown by 44% over the year.Impairment losses on loans and advances was 0.4 million euros in August.In August, the bank earned a net profit of 584 thousand euros.Comment by Margus Rink, Chairman of the Management Board of Coop Pank:“Coop Pank’s business volumes continued to grow steadily....

Coop Panga 2020 augusti majandustulemused:Panga klientide arv kasvas augustis 1 800 võrra ja ulatus kuu lõpuks 78 000-ni. Kliendibaas on aastaga kasvanud 43%Panga klientide hoiuste maht kasvas 34 miljoni euro võrra ulatudes augusti lõpu seisuga 684 miljoni euroni. Aastaga on panga hoiuste maht kasvanud 54%Panga neto laenuportfell kasvas kuuga 11 miljoni euro võrra ja jõudis augusti lõpu seisuga 583 miljoni euroni. Aastaga on panga laenuportfell kasvanud 44%Laenude allahindluse kulu oli augustis 0,4 miljonit eurotPank teenis augustis 584 tuhat eurot puhaskasumitCoop Panga juhatuse esimehe Margus Rinki kommentaar:„Coop Panga ärimahud jätkasid stabiilset kasvu. Augustis liitus meiega 1800 uut klienti. Laenuportfell kasvas 11 miljoni euro võrra. Klientide hoiused suurenesid rekordilise 34 miljoni euro võrra, millest äriklientide hoiused moodustasid...

VANCOUVER, British Columbia, Sept. 10, 2020 (GLOBE NEWSWIRE) — Avricore Health Inc. (TSXV: AVCR) (the “Company” or “Avricore”) announces that its Board of Directors and Shareholders have approved (subject to TSXV approval) the re-pricing of a total of 2,091,072 options to purchase common shares (“Options”) to an amended exercise price of $0.10 per Option (the “Re-Pricing”).The Re-Pricing of the Options was approved by the Board of Directors on February 2, 2020. The closing price of the Company’s common shares on the TSXV on January 31, 2020, prior to the approval of the Re-Pricing, was $0.03.150,000 of the Options had been issued on July 20, 2017 with an original exercise price of $0.15. 150,000 of the Options had been issued on September 27, 2017 at an original exercise price of $0.15....

PLEASANTON, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) — 10x Genomics, Inc. (NASDAQ: TXG) (the “Company”) today announced the pricing of an upsized underwritten public offering by the Company of its Class A common stock at a price to the public of $110.00 per share, before underwriting discounts and commissions. 10x Genomics is offering 4,000,000 shares of its Class A common stock, plus up to an additional 600,000 shares of its Class A common stock that the underwriters have the right to purchase at the public offering price, less the underwriting discounts and commissions. All of the shares are being offered by the Company. The offering is expected to close on September 15, 2020, subject to customary closing conditions.The offering is being made through an underwriting group led by J.P. Morgan Securities LLC, BofA Securities and Cowen...

  Mechelen, Belgium; 11 September 2020, 04.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) reports positive topline results in the NOVESA Phase 2a clinical trial with investigational ziritaxestat (GLPG1690) in patients with diffuse cutaneous systemic sclerosis (dcSSc).Ziritaxestat reached the primary endpoint of the study with a statistically significant change from baseline in the modified Rodnan Skin Score (mRSS) at Week 24, of -8.3 vs -5.7 for placebo.   NOVESA is a double-blind, placebo-controlled Phase 2a proof-of-concept trial evaluating the efficacy, safety and tolerability of ziritaxestat (GLPG1690) in 33 patients with dcSSc. DcSSc is a severe autoimmune disease with one of the highest mortality rates among rheumatic diseases2 with no drugs currently approved to treat the overall disease. Systemic sclerosis (SSc) affects...

  Mechelen, België; 11 september 2020, 04:30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) rapporteert topline resultaten in de NOVESA fase 2a klinische studie met ziritaxestat (GLPG1690) bij  patiënten met diffuse cutane systemische sclerose (dcSSc).Ziritaxestat behaalde een significant resultaat voor het primaire eindpunt, nl. het verschil ten opzichte van de baseline in de modified Rodnan Skin Score (mRSS) op 24 weken (-8,3 versus -5,7 bij placebo).NOVESA is een dubbelblinde, placebogecontroleerde fase 2a proof-of-concept-studie die de werkzaamheid, veiligheid en tolerantie van ziritaxestat (GLPG1690) bij 33 patiënten met dcSSc onderzoekt. DcSSc is een ernstige auto-immuunziekte met één van de hoogste sterftecijfers onder de reumatische aandoeningen2. Er zijn momenteel geen goedgekeurde medicijnen om het volledige ziektebeeld te...